European medicines agency grants orphan drug designation to rafael pharmaceuticals' cpi-613® (devimistat) for treatment of patients with relapsed or refractory burkitt's lymphoma

Cranbury, n.j., nov. 03, 2021 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the european medicines agency (ema) has granted orphan drug designation to cpi-613® (devimistat) for the treatment of burkitt's lymphoma.
RFL Ratings Summary
RFL Quant Ranking